Af­ter star­ring at ASH last fall, Gilead’s new Forty Sev­en crew col­ors in more promis­ing da­ta for ma­grolimab at AS­CO

We now know the full, ear­ly-stage sto­ry be­hind the drug that in­spired Gilead CEO Dan O’Day’s re­cent $5 bil­lion ac­qui­si­tion of Forty Sev­en.

Fol­low­ing up on their AS­CO ab­stract from a cou­ple of weeks ago, the team at Forty Sev­en is mak­ing their re­turn ap­pear­ance this week hold­ing clear­ly promis­ing ear­ly-stage da­ta on their lead drug ma­grolimab as they pon­der whether they should roll on a quest to ob­tain an ac­cel­er­at­ed ap­proval.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER